earnings
confidence high
sentiment neutral
materiality 0.85
Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M
REGENERON PHARMACEUTICALS, INC.
2021-FY EPS reported
$71.97
revenue$16,071,700,000
- Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.
- EYLEA U.S. net sales $1.55B (+15% YoY); full year $5.79B (+17%).
- $232M writedown of REGEN-COV inventory due to Omicron; EUA revised to exclude Omicron regions.
- FY2022 non-GAAP guidance: R&D $2.8B-$3.0B; SG&A $1.65B-$1.77B; gross margin 90-92%.
- Board authorized $3B share repurchase program.